Separately, William Blair cut Pieris Pharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, June 21st.
Pieris Pharmaceuticals Price Performance
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) last released its earnings results on Thursday, August 10th. The biotechnology company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.21. Pieris Pharmaceuticals had a negative return on equity of 90.41% and a negative net margin of 81.44%. The company had revenue of $20.06 million for the quarter, compared to the consensus estimate of $3.76 million. Research analysts expect that Pieris Pharmaceuticals will post -0.35 EPS for the current fiscal year.
Hedge Funds Weigh In On Pieris Pharmaceuticals
Several hedge funds have recently modified their holdings of PIRS. Tower Research Capital LLC TRC boosted its stake in shares of Pieris Pharmaceuticals by 9,665.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 21,581 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 21,360 shares in the last quarter. Raymond James & Associates boosted its stake in shares of Pieris Pharmaceuticals by 50.0% during the 4th quarter. Raymond James & Associates now owns 30,000 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 10,000 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Pieris Pharmaceuticals during the 1st quarter worth $32,000. Mirabella Financial Services LLP acquired a new stake in shares of Pieris Pharmaceuticals during the first quarter worth approximately $39,000. Finally, Two Sigma Investments LP acquired a new position in shares of Pieris Pharmaceuticals in the third quarter worth $43,000. 75.03% of the stock is currently owned by institutional investors and hedge funds.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.
- Five stocks we like better than Pieris Pharmaceuticals
- What to Know About Investing in Penny Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- Consumer Discretionary Stocks Explained
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Are Penny Stocks a Good Fit for Your Portfolio?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.